Thoratec On Track For Late 2015 HeartMate III Launch
This article was originally published in The Gray Sheet
Executive Summary
Enrollment has been completed in the firm's 50-patient trial to support a European CE mark of its next generation HeartMate III.
You may also be interested in...
Thoratec Seeks 'Cultural Revolution' As Rival HeartWare Makes Strides
The long-time leader of the ventricular assist device market Thoratec is implementing plans to get back on track for future growth, while rival HeartWare recently reported rapid global expansion and aggressive R&D investments.
Thoratec Looks To Next-Generation LVADs To Revive Sinking Sales
Thoratec reported a near 10 percent year-over-year decline in revenue in the second quarter; physicians have become more selective about which patients to implant with a HeartMate II ventricular assist device, the firm says. The company is looking to next-generation of HeartMate products as well as the technology it acquired in the Apica deal to help it return to growth.
Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.